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A mathematical model for growing metastases
on oncologists’s service
D. Barbolosi, A. Benabdallah, S. Benzekry, J. Ciccolini, C. Faivre, F. Hubert, F.
Verga, B. You
Abstract The dual classification of cancer as localized or metastatic disease is one
of the key point in the elaboration of the best therapy for each patient. Neverthe-
less, many studies reveal that part of these localized diseases are already metastatic.
The presence of undetectable or micro-metastases explains the necessity of adjuvant
chemotherapies after resection of the primary tumor even for some T1N0M0 cancer.
There is probably a continuum between these two stages.
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We expose here how a mathematical model of growing metastases could reflect
this continuum of the disease and how such a model could help the oncologists in
the choice of the treatment. This phenomenological model is based on a structured
transport equations with non local boundary condition describing the evolution of
the density of metastasis. Thanks to this model, we forge a new numerical index,
that we call Metastatic Index, able to reveal either the micro-metastatic state of the
patient, or the visible metastatic one. Numerical illustrations show how this new
index can be used.
1 A family of model of growing metastases
1.1 Tumor growth models with treatment
We assume that the dynamic of the primary tumor is given by some ODE equations.
The simplest one is the Gompertz equation
x′p(t) = axp ln
(
θ
xp
)
(1)
where a quantifies the growth rate of the tumor and θ denotes the carrying capac-
ity of the media or the maximal size that the tumor can reach. It expresses that
the growth rate of the tumor
x′p
xp
follows some exponential law. The influence of a
chemotherapy can then be seen as a shift of this rate:
x′p = axp ln
(
θ
xp
)
− γc(t,xp) := g(t,xp) (2)
where γc reflects the pharmacokinetics and the pharmacodynamics of the chemother-
apy treatment. The determination of this function γc is discussed in [9, 8].
To handle tumoral neo-angiogenesis of the tumor, Folkman & col. propose in [5]
to see θ as a time variable function characteristic of the vascularization of tumor.
x′p = axp ln
(
θ
xp
)
− xpγc(t,xp) := g1(t,xp,θ), (3)
θ ′(t) = cxp−dθx
2
3
p − γaa(t,θ) := g2(t,xp,θ) (4)
where the terms cxp and dθx
2
3
p represent, respectively, the endogenous stimulation
and inhibition of the vascularisation and γaa the action of an anti-angiogenic drug.
We refer to these models as
X ′ = G(t,X(t)) := (g1(t,xp,θ),g2(t,xp,θ)) (5)
A mathematical model for growing metastases on oncologists’s service 3
1.2 Metastatic growth models
Our first approach consists in deriving a transport equation for the metastatic colony
distribution ranged by their size x. We suppose that the primary tumor is generated
by a single cell at t = 0 and grows with the rate g(t,x) per unit time where x is
the tumor size represented by the number of cells in the tumor. The growing tumor
emits metastatic cells with the rate β (x). Each metastatic cell develops into a new
tumor, which also grows at rate g(t,x) and emits new nuclei of metastasis just as
the primary tumor does. Let v(x, t) represent the colony size distribution with cell
number x at time t, actually v(x, t)dx means the number of metastatic tumors whose
sizes range from x and x+dx at time t. In the case considered here we suppose that
the nuclei of colonization are located far enough from each other so that their ranges
do not overlap for a long time period. The dynamics of the colony size distribution
is given by the following Mac-Kendrick Von Foerster equation:


∂
∂ t
v(t,x)+ ∂
∂x
[g(t,x)v(t,x)] = 0, x ∈ [1,b), t ≥ 0
g(1)v(t,1) =
∫ b
1 β (x)v(t,x)dx + β (xp(t))
v(0,x) = 0,
(6)
with g and xp defined in (2).
We have to deal with a transport equation with a nonlocal boundary condition
and an initial data equals to zero which supposes that there is no metastatic tumor at
time t = 0. The boundary condition means that the number of metastatic cells newly
created per unit time at time t is the total rate of occurences of metastases due to
metastatic tumors (corresponding to the integral term) and the primary tumor.
The colonization rate β (x) is choosen as β (x) = mxα , where m is the colonization
coefficient and α is the fractal dimension of blood vessels infiltrating the tumor.
The parameter α expresses how the blood vessels geometrically distribute in or on a
tumor. If the vascularity is superficial the fractal dimension α is assigned to be 2/3
because we suppose that the tumor has the shape of a sphere; hence, the surface area
is proportional to 2/3. Otherwise, in the case of a vascularization homogeneously
distributed in the whole tumor, α is supposed to be equal to 1. This model was
introduced by Iwata et al. [6] for non-treated tumors. An efficient discretization
of the problem is proposed in [1], the extension of the model to tumor treated by
chemotherapy can be found in [11, 12]. Let us define the metastatic index
MI
θmax
θmin
=
∫ θmax
θmin
v(t,x)dx. (7)
with 1 ≤ θmin ≤ θmax ≤ θ . We recall that θ represents the maximal size of the tu-
mor, its value classicaly taken between 1011 and 1012 corresponds to a mass tumor
of 100g to 1kg. The choice θmin = 1,θmax < 10
8 leads to the evaluation of mi-
crometases, whereas the choice θmin = 10
8, θmax = θ corresponds to visible ones.
The metastatic index MI is in model (6) determined through the four parameters
a,θ ,m,α . Each of these parameters has to be determined for each patient. The first
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two parameters can be estimated thanks to two values of the size of the primary
tumors. A population study is needed to obtain mean values of parameters of m,α
as well as their distribution.
Remark 1 (How to traduce in the model the resection of the primary tumor?). The
resection of the primary tumor can be interpreted in our model as sudden diminution
of the size of the primary tumor. The function xp becomes close to 0 at T1 time
corresponding to the surgery. Note that Peeters & al have also suggested in [10] that
removal of a primary colorectal tumor resulted in an increase in metabolic activity
in its liver metastasis (see also [4]). They indicate that the primary tumor suppressed
angiogenesis in its distant metastasis, and that removal of the primary lesion caused
a flare-up in vessel neoformation and, thus, enhanced metabolic activity in its liver
metastasis. This stimulation of angiogenic activity could be integrated in our model
, by a stiff change in the value of m.
Remark 2 (How to take into account for tumoral angiogenesis?). We assume that
the metastatic colony distribution v depends not only on the time t and the size x,
but also on the carrying capacity θ . The balance equation then reads
∂
∂ t
v(t,X)+div[G(t,X)v(t,X)] = 0 with X = (x,θ) and G given in (5). (8)
We refer to Benzekry [3, 2] for more details on the model and its discretization.
2 How can this mathematical model be helpful for oncologist?
2.1 Calibration of the parameters of the model
We first exhibit the good behavior of the model (6). Koscielny & al made in Insti-
tut Gustave Roussy [7] a retrospective study, over more than twenty years, on 2648
patients with a breast cancer. They reported the percentage of patients (without ad-
juvant chemotherapy) with at least one metastase (detectable or not) with respect to
the size of the initial tumor.
Table 1 presents a comparison of these results with percentage from our model.
To simulate a panel of patients, we choose the parameters m and α with a normal
distribution (the respective parameters of the distribution are µm = 2.5×10
−8, σm =
10−8 and µα = 0.48, σα = 0.3). The similarity between observed and predicted data
is emphasized by the value r2 = 0.98 of correlation coefficient.
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Size of the initial tumor Computed percentage Percentage observed in [7]
1–2.5cm 25.5% 27%
2.5–3.5cm 44.25% 42%
3.5–4.5cm 60.5% 56.7%
4.5–5.5cm 68.6% 66.5%
5.5–6.5cm 75.5% 72.8%
6.5–7.5cm 78.25% 83.8%
7.5–8.5cm 83.25% 81.3%
>8.5cm 89.25% 92%
Table 1 Percentage (computed vs observed) of patients having at least one metastase with respect
to the size of the primary tumor
2.2 Influence of the surgery
In this simulation, the values of the parameters a,θ ,α are fixed to a = 4.71×10−4,
θ = 1012, α = 0.5. Initialy, the value of the parameter m is 2.5×10−8. The bigger
the primary tumor is, the bigger is m. We assume that the resection is almost radical
(10 cells left). To simulate different sizes of tumors, we choose in table 2 m =
2.5× 10−7, m = 2.5× 10−6, m = 2.5× 10−7. Remark that the model is able to
quantify the impact of the surgery on the possible recidive of the disease.
Size of the initial tumor MI after 5 years MI after 10 years
109 0 1
5×1010 3 13
1011 5 19
Table 2 Evolution of the metastatic index after surgery
2.3 Inter individualization of an adjuvant treatment
Let us now consider a classical treatment of breast cancer [13]. The standard proto-
col of 6 cycles of 21 days consists in 75mg of Docetaxel and 100mg of Epirubicin.
The pharmacokinetics and pharmacodynamics of the drugs follow the model devel-
opped in [9, 8]. All the patients are assumed to be metastatic at diagnosis with a
primary tumor of 1g. Table 3 quantifies the variability of the efficacity of the treat-
ment with respect to m. The model allows to rationalize the number of cycle of
chemotherapy to choose for each patient in order to avoid the longer as possible the
recidive risk.
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m 6 cycles 9 cycles 12 cycles
1.3×10−7 1 0 *
2.7×10−7 2 1 0
4.0×10−7 3 2 1
6.1×10−7 5 4 3
Table 3 Estimation of the number of visible metastasis MIθ
108
with respect to the aggressivity of
the tumor. The cases presenting no metastatic risk are in bold.
2.4 Combined cytotoxic and antiangiogenic agents
We use the model (8) to exhibit the importance of the scheduling in a combined
treatment. We simulate in Figure 1 a 24h injection of 500mg/m2 Etoposide followed
or foreruned by a 90 minutes injection of 5mg/kg of Bevacizumab.
Fig. 1 Influence of the scheduling in a combined therapy. (a) Tumor growth, (b) visible metastasis,
(c) carrying capacity, and (d) total number of metastasis
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Conclusion
The developpment of such metastatic model is fundamental to complete the usual
classifications (TNM, SBR, ...) of the disease and to optimize the synergy be-
tween the different available treatments (surgery, radiotherapy, drugs...). Besides,
the scheduling plays a crucial role in the efficacity of the treatment (see [14, 15]).
Our models are particularly flexible and can describe a large spectrum of thera-
pies, as combined cytotoxic and antiangiogenic agents (with the use of model (8))
and then optimize the organization of all treatment for each patient.
We are currently validating in vivo such models on little animal. The choice of
phenomenological model is crucial in view of clinical applications. One of the well-
known difficulty of using mathematical approach in clinical application is obviously
the identification of the parameters involved in the models. The advantage of these
phenomenological models is to involve little parameters that we can expect to esti-
mate properly in a finite time.
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